|Articles|October 1, 2001

Siplizumab studies show safety as psoriasis Tx

In three studies for safety, patients show improvement in psoriasisas measured by PASI score

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME